StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Free Report) in a research note released on Thursday. The firm issued a hold rating on the stock.
NovaBay Pharmaceuticals Price Performance
NBY stock opened at $0.54 on Thursday. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $44.80. The company has a market capitalization of $582,116.00, a price-to-earnings ratio of 0.00 and a beta of 0.83. The business has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $3.31.
NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 304.39% and a negative net margin of 80.76%. The business had revenue of $2.40 million during the quarter. Sell-side analysts anticipate that NovaBay Pharmaceuticals will post -5.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Recommended Stories
- Five stocks we like better than NovaBay Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 8/12 – 8/16
- The How And Why of Investing in Oil Stocks
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.